Landfar Bio-medicine's high P/S ratio may not be justified d...

Landfar Bio-medicine's high P/S ratio may not be justified due to its poor revenue performance. Investors expecting a turnaround may face disappointment if the P/S falls to levels in line with recent growth rates. Without significant improvement, it's hard to prevent the P/S ratio from declining to a more reasonable level.